References
1. Matzdorff A, Ledig B, Stuecker M, Riess H. Practice Patterns for Prophylaxis and Treatment of
Venous Thromboembolism in German CancerPatients. Oncol Res Treat. 2016;39(4):194-201.
DOI: https://doi.org/10.1159/000444734.
2. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of
a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902–4907.
3. Ikushima S, Ono R, Fukuda K, Sakayori M, Awano N, Kondo K. Trousseau's syndrome: cancer-
associated thrombosis. Japanese Jour of Clin Oncol 2016; 46(3); 204–208. DOI:
https://doi.org/10.1093/jjco/hyv165
4. Pabinger I, Riedl J. Direct oral anticoagulants: now also for prevention and treatment of cancer-
associated venous thromboembolism?. Hematology Am Soc Hematol Educ Program
2017;2017(1):136-143.
5. Easaw JC, Budgell S, Czaykowski PM, et al. Canadian consensus recommendations on the
management of venous thromboembolism in patients with cancer. Part 1: prophylaxis. Current
Oncology 2015; 22(2): 133-43. Available at: <http://www.current-
oncology.com/index.php/oncology/article/view/ 2586/1765>. Date accessed: 18 feb. 2019. DOI:
http://dx.doi.org/10.3747/co.22.2586.
6. Khorana AA. Risk assessment for cancer-associated thrombosis: what is the best approach?
Thromb Res. 2012;129(1):S10-5. DOI: https://doi.org/10.1016/S0049-3848(12)70009-9.
7. Khorana AA. Simplicity versus complexity: an existential dilemma as risk tools evolve. Lancet
Haematol. 2018 Jul;5(7):e273-e274. https://doi.org/10.1016/S2352-3026(18)30067-X.
8. van Es N, Franke VF, Middeldorp S, Wilmink JW, Büller HR. The Khorana score for the
prediction of venous thromboembolism in patients with pancreatic cancer. Thromb
Res. 2017;150:30-32. DOI: https://doi.org/10.1016/j.thromres.2016.12.013.
9. van Es N, Di Nisio M, Cesarman G et al. Comparison of risk prediction scores for venous
thromboembolism in cancer patients: a prospective cohort study. Haematologica 2017; 102(9):
1494–1501. DOI: https://doi.org/10.3324/haematol.2017.169060
10. Parker A, Peterson E, Lee AYY, et al. Risk stratification for the development of venous
thromboembolism in hospitalized patients with cancer. J Thromb Haemost. 2018;16(7):1321-
1326. DOI: https://doi.org/10.1111/jth.14139.
11. Kuderer NM, Lyman GH. Guidelines for treatment and prevention of venous thromboembolism
among patients with cancer. Thromb Res. 2014;133 (2):S122-7. DOI:
https://doi.org/10.1016/S0049-3848(14)50021-7.
12. Lyman GH, Bohlke K, Khorana AA, et al. Venous Thromboembolism Prophylaxis and
Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice
Guideline Update 2014. Jour Clin Oncol 2015; 33(6): 654-656.
